Loading organizations...
§ Private Profile · Houston, TX, USA
Clinical-stage biotechnology company developing allogeneic T-cell therapies to restore immunity against viral diseases in immunocompromised patients.
Based in Waltham, Massachusetts, AlloVir is a clinical-stage biotechnology company that develops allogeneic, off-the-shelf T-cell therapies to restore immunity against viral diseases in immunocompromised patients. Following the discontinuation of its late-stage clinical trials for its lead candidate, the company reduced its workforce by 95 percent in early 2024 and subsequently merged with Kalaris Therapeutics to pivot toward retinal disease treatments. Prior to this restructuring, the enterprise secured significant capital, including a $120 million Series B financing round in 2019 and a $276 million initial public offering in 2020. The firm's foundational research originated at Baylor College of Medicine, and its operations have been backed by notable institutional investors such as ElevateBio, Fidelity Management, and Samsara BioCapital. Originally established as ViraCyte, the company was founded in 2013 by Ann Leen, Helen Heslop, Cliona Rooney, Juan Vera, and Malcolm Brenner.
AlloVir has raised $129.0M across 2 funding rounds.
AlloVir has raised $129.0M in total across 2 funding rounds.
AlloVir has raised $129.0M across 2 funding rounds. Most recently, it raised $120.0M Series B in May 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 30, 2019 | $120M Series B | Fidelity Management & Research Company | — | Announced |
| Aug 21, 2017 | $9M Grant | Cancer Prevention And Research Institute OF Texas | — | Announced |
AlloVir has raised $129.0M in total across 2 funding rounds.
AlloVir's investors include Fidelity Management & Research Company, Cancer Prevention and Research Institute of Texas.